Why Canopy Growth (TSX:WEED) Stock Fell 25% in August 2019

Why Canopy Growth Corp (TSX:WEED)(NYSE:CGC) stock remains a top pick for cannabis investors.

| More on:
Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

Shares of Canada’s leading pot stock Canopy Growth (TSX:WEED)(NYSE:CGC) fell 25% in August 2019. Canopy Growth has lost close to $4 billion in market value last month. So, what drove Canopy Growth stock lower?

Canopy’s first-quarter results

Canopy Growth announced its fiscal first quarter of fiscal 2020 (ended in June) results on August 14, 2019. It reported revenue of $90.5 million with adjusted earnings per share (or EPS) of -$0.30 in the first quarter. This was above analyst revenue estimates of $86 million and EPS estimate of -$0.37.

However, Canopy Growth stock fell 14.5% on August 15, as investors were unimpressed with the company’s unadjusted net loss amounting to a massive $1.28 billion. Canopy Growth attributed the loss to its expansion efforts as well as its acquisition of Acreage Holdings.

Earlier this year, Canopy Growth agreed to acquire Acreage for $3.4 billion. Acreage Holdings is a U.S-based vertically integrated cannabis company. Investors were also worried about less than impressive sales in Canopy’s oils and gels business segment, driving its stock lower.

Constellation Brands books huge loss

Canopy Growth stock fell 6% on August 27 after its largest investor, Constellation Brands (NYSE:STZ) expects to book a loss of $54.8 million in the second quarter of fiscal 2020 (ended in August).

Constellation has attributed this loss to its investment in Canopy Growth. The total loss in the six months is expected to be $132 million for Constellation.

Constellation Brands had initially invested $190 million in Canopy Growth back in 2017 for a 10% stake. It has since increased its investments to $4 billion and now holds over 35% in Canopy Growth.

The last month saw several Cannabis stocks lose value. Aurora Cannabis was down 12%, while CannTrust,  and Hexo lost 26% and 6% respectively. The Horizons Marijuana Life Sciences Index ETF fell 13% in August 2019.

What next for Canopy Growth?

Canopy Growth investors have had a few rough months heading into September. The stock has fallen by a significant 54% since April 29, 2019. In July of this year, Canopy Growth’s board of directors ousted its founder and CEO Bruce Linton due to its piling losses.

While Canopy Growth is still booking massive losses, its management expects the firm to reach profitability within the next three to five years. It will continue to grow revenue at a considerable pace.

The total available market is estimated to expand robustly over the next few years and Canopy wants to focus on laying a strong foundation to benefit from this growth.

Canopy Growth wants to develop intellectual property, build brand value, expand to international markets and scale efficiently to grow sales as well as the bottom line.

During the earnings call, company CEO Mark Zekulin stated, “We are fixated on the process of evolving from builders to operators over the remainder of this fiscal year, meaning that as our expansion program comes to a close in Canada, and as new value-add products come to market in Canada, we demonstrate a sustainable, high margin, profitable Canadian business.”

Canopy Growth stock is one of the largest players in the cannabis space. It is trading at an attractive price after the recent pullback. Analysts also remain optimistic about Canopy and have a 12-month average target price of $56.67 which is 80% higher than the current trading price.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »